Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned: the labeling supports the plaque psoriasis indication, active ingredient, and general topical application instructions, as well as the existence/fielding of the AhR agonist mechanism. However, multiple claims about efficacy/mechanism effects (e.g., immune modulation and reduced inflammation) and multiple specific adverse reactions are not supported by the provided label excerpts; also the FDA approval timing is not supported by the supplied information.
Category Scores
Accurate Statements
Vtama cream is a topical treatment approved for the relief of signs and symptoms of plaque psoriasis in adults.
Label 1.1: “VTAMA® cream is indicated for the topical treatment of plaque psoriasis in adults.” (Provided excerpts do not include the phrase “relief of signs and symptoms,” but the indicated population and topical treatment for plaque psoriasis are supported.)
Vtama cream is prescribed to manage plaque psoriasis.
Label 1.1: “VTAMA® cream is indicated for the topical treatment of plaque psoriasis in adults.”
Vtama cream contains tapinarof as its active ingredient.
Label 12.1: “Tapinarof is an aryl hydrocarbon receptor (AhR) agonist.” (Tapinarof is the active therapeutic moiety referenced throughout label.)
Tapinarof is a non-steroidal aryl hydrocarbon receptor (AhR) agonist.
Label 12.1: “Tapinarof is an aryl hydrocarbon receptor (AhR) agonist.” (The label excerpt does not explicitly state “non-steroidal.”)
Tapinarof works differently from other topical corticosteroids.
Partial support only via mechanism statement: Label 12.1 identifies tapinarof as an AhR agonist, while corticosteroids are not described in the provided excerpts (no direct label text comparing vs corticosteroids).
Tapinarof works differently from systemic medications.
Partial support only: label excerpt focuses on topical AhR agonist mechanism and notes mechanisms are unknown (no direct systemic comparison text in provided excerpts).
Unsupported Statements
Vtama cream is applied directly to the affected areas of the skin.
Label 2 only states to “Apply a thin layer of VTAMA cream to affected areas once daily.” It supports affected-area topical application, but “directly” wording is not explicit; treat as unsupported/over-specific.
Tapinarof works by modulating the immune response in the skin.
Label 12.1 states tapinarof is an AhR agonist, but also says: “The specific mechanisms by which VTAMA cream exerts its therapeutic actions are unknown.” No immune-modulation claim is provided in the supplied excerpts.
Tapinarof reduces inflammation associated with psoriasis.
Provided label excerpts do not state that tapinarof reduces inflammation associated with psoriasis.
Vtama cream received FDA approval in July 2022.
The supplied label excerpts do not provide an FDA approval date.
Common side effects of Vtama cream include upper respiratory tract infections.
Specific adverse reactions are not provided in the excerpts; Table 1 reaction list is not included. No URTI is shown in the provided text.
Common side effects of Vtama cream include headache.
Specific adverse reaction rows from Table 1 are not included in the provided excerpts; headache is not shown.
Common application site reactions of Vtama cream include itching.
Specific application-site reaction rows from Table 1 are not included in the provided excerpts; itching is not shown.
Common application site reactions of Vtama cream include rash.
Specific application-site reaction rows from Table 1 are not included in the provided excerpts; rash is not shown.
Common application site reactions of Vtama cream include burning.
Specific application-site reaction rows from Table 1 are not included in the provided excerpts; burning is not shown.
Common application site reactions of Vtama cream include stinging.
Specific application-site reaction rows from Table 1 are not included in the provided excerpts; stinging is not shown.
Common application site reactions of Vtama cream include redness.
Specific application-site reaction rows from Table 1 are not included in the provided excerpts; redness is not shown.
Vtama cream offers a topical, non-steroidal option for psoriasis management.
The excerpt supports topical treatment (1.1) and identifies tapinarof as an AhR agonist (12.1), but does not explicitly describe VTAMA as “non-steroidal.”
The efficacy of Vtama cream is distinct from other treatments available for plaque psoriasis.
The provided excerpts do not include comparative efficacy against other treatments.
The side effect profile of Vtama cream is distinct from other treatments available for plaque psoriasis.
The provided excerpts do not include comparative safety against other treatments.
Contradictions
Important Omissions
Details of the specific adverse reactions that are “at least 1%” and exceed vehicle rates for plaque psoriasis (Table 1) and whether they are application-site reactions—these are necessary to support the enumerated “common side effects/application site reactions” claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several efficacy/mechanism-effect statements and a list of specific common adverse reactions are not supported by the provided label excerpts. Unsupported safety portrayal could mislead risk expectations, though no explicit contraindications, boxed warnings, or direct contradictions were included in the claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided label excerpts (mechanism-effect statements, FDA approval month, and specific adverse reaction list).
Suggested Improvement
Limit mechanism discussion to what the label states (AhR agonist; specific therapeutic mechanisms unknown) and avoid asserting specific adverse reactions or “common” frequency unless the provided Table 1 rows are cited. Remove or verify the FDA approval timing using label text provided.